Justin H.
His PCP said he was fine. His labs said otherwise. He acted before it was too late to prevent anything.
34 lbs lost. HOMA-IR from 3.6 to 1.0. Testosterone from 412 to 561 — without TRT. ApoB from 98 to 76. Prediabetes trajectory reversed at 36, before his father's timeline caught up with him.
He Did the Math — and Didn't Like the Answer
Justin is a 36-year-old senior software architect at a Series-C SaaS company — engaged, getting married in 11 months, and working 70-hour weeks during release cycles from a chair he barely leaves. Takeout five nights a week. Almonds, protein bars, and jerky during deep-work sessions. A gym membership 14 months unused. A Whoop he wore for 8 months and stopped checking. A CGM trial that revealed glucose spikes bigger than he expected. His PCP's verdict: "In good shape — just need to drop a few."
Justin didn't buy it. He listens to Huberman and Attia. He knew his fasting insulin was borderline. He knew his A1c was in early prediabetes. He had watched his father get diagnosed with Type 2 diabetes at 51 and his uncle at 47. He had done the math on what his current trajectory looked like at 46, at 51, at 56 — and he refused to wait for the diagnosis before acting. He wanted to intervene at 36, while the trajectory was still changeable.
He came to FLOA with a precise goal: not weight loss as the primary objective, but metabolic correction — A1c, fasting insulin, HOMA-IR back into healthy range, ApoB toward longevity targets, testosterone recovered through fat loss rather than TRT. The wedding in 11 months was a real motivator. The next 30 years of his family history was the actual one.
What "Fine" Actually Looked Like
- A1c 5.8% — early prediabetes; fasting glucose 99 mg/dL — at the upper boundary of normal
- HOMA-IR 3.6 — established insulin resistance; fasting insulin 16 mIU/L
- ApoB 98 mg/dL — elevated for longevity medicine targets; cardiovascular risk accumulating quietly
- Total testosterone 412 ng/dL — low-normal for a 36-year-old; suppressed SHBG; elevated estradiol for a male — secondary to adiposity
- hs-CRP 2.2 mg/L — mild systemic inflammation; ALT 36 — borderline liver stress
- Visceral adiposity disproportionate to BMI of 31.5 — classic desk-worker phenotype; waist 41 inches
- Father diagnosed T2D at 51; uncle at 47 — strong familial loading putting Justin on a predictable timeline
- Completely desk-bound 11 hours daily; gym membership unused for 14 months
- "Thinking food" pattern: continuous desk snacking on almonds, protein bars, jerky — caloric without structure
- Takeout 5 nights/week — no meal architecture in place
- Sleep 6.5 hours during release cycles — insufficient for metabolic recovery or hormonal optimization
- Multiple failed self-directed attempts: 5/3/1 abandoned, standing desk unused, macro tracking lasted 19 days
Preventive Medicine Framing — Built to Taper Off
Comprehensive preventive panel: fasting insulin, HOMA-IR, A1c, ApoB, Lp(a), hs-CRP, GGT, full lipid with particle sizing, full thyroid, vitamin D, B12, ferritin. Whoop and CGM data from prior self-experimentation reviewed — revealing more than his PCP's standard panel had caught. Lifestyle mapping documented the actual desk-bound day, the "thinking food" pattern, the gap between his health-podcast literacy and his real habits. Explicit Metabolic Independence framing from the start: the goal was to taper off, not to create dependency.
Tirzepatide chosen for its dual GIP/GLP-1 mechanism — particularly useful for insulin resistance correction in a pre-disease state. Started at 2.5mg weekly using an explicit Lowest Effective Dose strategy given Justin's preventive (not therapeutic) framing. Escalated to 5mg at week 6 and held there throughout — never went higher because his response made it unnecessary. Target was metabolic correction, not maximum weight loss velocity. Taper to 2.5mg every 10 days began at month 8.
At 36 with limited training history and 14 months of gym avoidance, muscle development was as important as fat loss. CJC-1295/Ipamorelin added from month 1 for sleep architecture improvement and GH-axis support for lean mass development during the fat loss arc. A patient losing weight rapidly without supporting lean mass development arrives lighter but metabolically compromised — a worse long-term outcome than a slower recomposition.
AOD-9604 added at month 2 for visceral fat mobilization — the fat depot most tightly linked to insulin resistance, testosterone suppression, and ApoB elevation in Justin's profile. At HOMA-IR 3.6 with disproportionate central adiposity for his BMI, visceral fat was the mechanism driving every metabolic marker that mattered. The Metabolic Two-Piece: tirzepatide managing appetite and insulin dynamics, AOD-9604 mobilizing the fat type that was causing the damage.
Three strength sessions weekly with compound lifts — deliberately programmed against his prior failed 5/3/1 attempt. Slower progression, less ego-driven loading, more recoverable volume. The prior failure wasn't a discipline failure; it was a program design failure — too aggressive for a desk worker during release cycles. One Zone 2 cardio session weekly. The program was built to survive a crunch week, not to require ideal conditions.
Months 3–6 introduced staged fasting: 16:8 daily eating window, then 24-hour fasts twice monthly, then a single 48-hour fast at month 6 framed as a longevity intervention targeting autophagy. The tirzepatide made the transition to extended fasting genuinely manageable — removing the hunger spikes that had made every prior dietary attempt unsustainable for a desk worker with continuous access to food. Testosterone held off — rechecked at month 6 after fat loss (561 ng/dL, fully recovered without TRT).
Phase by Phase
Desk Snacking Eliminated — Strength Training Restarted
Tirzepatide and CJC-1295/Ipamorelin initiated. Down 9 lbs. The "thinking food" snacking pattern — almonds, protein bars, constant desk grazing — eliminated within the first two weeks as tirzepatide removed the background hunger that had driven it. Takeout replaced with a meal service. Strength training restarted with deliberate light loads — no ego, sustainable from week one.
→ Down 9 lbs; desk snacking gone; strength training restarted
AOD-9604 Added — ApoB Already Moving
Titrated to 5mg tirzepatide. AOD-9604 added for visceral fat mobilization. Down 16 lbs total. ApoB rechecked at 84 — already a 14-point improvement from baseline 98. Waist reduction beginning to show. Compound lift progression on track. Release-cycle sleep protection protocol preventing the program abandonment that had ended every prior attempt.
→ Down 16 lbs; ApoB 84; AOD-9604 active; lifts progressing
Sweet Spot Reached — Fasting Introduced
Held at 5mg — no escalation needed. Down 22 lbs. The "Sweet Spot" reached: tirzepatide at minimum effective dose producing maximum sustainable results. Staged FLOA fasting introduced: 16:8 eating window established. Compound lift numbers progressing well — the program surviving release cycle weeks without abandonment for the first time in his adult life.
→ Down 22 lbs; sweet spot at 5mg; fasting window established
Testosterone Recovers Without TRT — A1c Into Healthy Range
Still at 5mg. Down 28 lbs. Total testosterone rechecked: 561 ng/dL — up 149 points from baseline 412, entirely through fat loss. TRT never initiated. A1c 5.4% — out of prediabetic range, into healthy. ApoB 76. The metabolic markers he had come in to correct were moving in every direction he had targeted. 24-hour monthly fasts established.
→ Down 28 lbs; T 561 without TRT; A1c 5.4%; ApoB 76
34 lbs Lost — Protocol Tapering — Wedding-Ready
Down 34 lbs at 198 lbs. Waist from 41 to 33 inches. DEXA confirmed: 28 lbs fat lost, 4 lbs lean mass gained. Tirzepatide reduced to 2.5mg every 10 days — beginning the taper toward Metabolic Independence, three months ahead of the wedding. Alcohol reduced from 4–6 drinks weekly to 2 without being asked. Strength training now a fixed part of his week regardless of release cycle status.
→ 34 lbs lost; waist 33″; tirzepatide tapering; wedding-ready
"Justin's PCP told him he was fine. His HOMA-IR was 3.6. His testosterone was suppressed by adiposity. His ApoB was quietly building cardiovascular risk. His A1c was in early prediabetes. 'Fine' is a low bar when your father is on metformin at 51 and your uncle is on insulin at 47. The most powerful intervention in preventive medicine is acting 15 years before the diagnosis — when the trajectory is still fully reversible. That window closes."
What Changed at 8 Months
Prediabetes Prevented
A1c from 5.8 → 5.4%. HOMA-IR from 3.6 → 1.0. Fasting insulin from 16 → 6 mIU/L. The metabolic trajectory his family history had written — interrupted at 36, before it became irreversible.
Body Composition
34 lbs lost (232 → 198). 28 lbs fat, 4 lbs lean mass gained per DEXA. Waist from 41 → 33 inches. Visceral adipose tissue reduced approximately 35% — the fat depot driving every metabolic marker that mattered.
Testosterone — No TRT
Total testosterone from 412 → 561 ng/dL — a 149-point recovery through fat loss alone. TRT was considered and deliberately withheld. Fat loss restored it. SHBG and estradiol both normalized.
Cardiovascular Risk
ApoB from 98 → 76 mg/dL — into longevity medicine target range. hs-CRP from 2.2 → 0.8 mg/L. ALT from 36 → 21. The quiet cardiovascular risk accumulation his PCP hadn't flagged — reversed.
Strength & Lifestyle
Sustainable strength training now a fixed weekly habit — surviving release cycles for the first time. Alcohol reduced from 4–6 → 2 drinks/week organically. Meal service replaced takeout. Sleep discipline holding.
Medication Independence
Tirzepatide tapering to 2.5mg every 10 days at month 8 — on trajectory for full Metabolic Independence by month 18. Built to taper off, not to create permanent dependency.
| Category | What Changed |
|---|---|
| Prediabetes | A1c 5.8 → 5.4%; HOMA-IR 3.6 → 1.0 — trajectory interrupted before diagnosis |
| Testosterone | 412 → 561 ng/dL without TRT — secondary suppression from adiposity fully reversed |
| ApoB | 98 → 76 mg/dL — into longevity medicine target range in 8 months |
| Waist | |
| Desk Snacking | Constant "thinking food" grazing pattern — eliminated within 2 weeks of tirzepatide initiation |
| Takeout | 5 nights/week → replaced with structured meal service; food architecture finally in place |
| Strength Training | 14 months unused gym membership → fixed 3x/week habit surviving release cycles |
| Alcohol | 4–6 drinks/week → 2 drinks/week — organic reduction without being prescribed |
| Family History | Father's T2D at 51, uncle's at 47 — Justin's trajectory diverged from theirs at 36 |
| Wedding | In the shape he wanted to be in — three months early, not scrambling at the finish line |
"My PCP told me I was fine. But I knew my fasting insulin was borderline, my A1c was creeping up, and my father and uncle were both on diabetes medications before 55. I didn't want to wait until I had the diagnosis to start acting. FLOA treated this as what it was — a preventive intervention, not a weight loss program. Eight months later my insulin resistance is gone, my testosterone recovered without TRT, my ApoB is where longevity doctors want it, and I got married in the best shape of my adult life. The wedding was the short-term win. The next 30 years is the actual goal."
Clinical Takeaways
Justin's case makes an argument that most medical practice doesn't have time to make: the best moment to intervene in metabolic disease is years before the diagnosis, when the trajectory is fully reversible and the intervention required is a fraction of what it will be later. At HOMA-IR 3.6 and A1c 5.8, Justin was not sick by any standard diagnostic criteria. He was on a trajectory. His PCP saw a normal result. His family history, his lab trends, and his lifestyle audit told a different story — one that a preventive medicine framing was designed to read.
The testosterone outcome deserves specific attention. At 412 ng/dL, Justin had low-normal testosterone that most hormone clinics would have treated with TRT immediately. FLOA held off, hypothesizing that the suppression was secondary to adiposity — elevated estradiol from visceral fat aromatization, suppressed SHBG, and chronic metabolic stress. The month 6 recheck at 561 ng/dL confirmed it. Fat loss restored what TRT would have replaced — and without creating the fertility, pituitary suppression, and dependency concerns that exogenous testosterone introduces in a 36-year-old planning his future.
The program design also mattered. Justin had failed 5/3/1, macro tracking, a standing desk, and a CGM. Not because he lacked discipline — he had plenty of it in his professional life — but because every prior attempt had been designed for ideal conditions. Release cycles happen. The protocol that survives imperfect conditions is the one that produces long-term outcomes. Building a strength program specifically against his prior failure mode, and using tirzepatide to remove the desk-snacking pattern that had undermined every prior dietary attempt, were the structural changes that made the difference.
The Best Time to Intervene Is Before the Diagnosis
If you're in your 30s or 40s, your labs look "fine," and you have a family history that tells a different story — the window to act is now. Prediabetes, insulin resistance, and suppressed testosterone don't wait for the diagnosis to start doing damage. Neither should you.
Individual results vary. This case study is for educational purposes only. © Dr. Jones DC — FLOA Protocol.